

Our most advanced PGT-A platform


With PGTaiSM 2.0 technology we provide greater clinical confidence in identifying euploid embryos for transfer, with the aim of reducing the risk of miscarriage

The aim of PGT-A is to identify euploid embryos and increase the chance of producing a healthy pregnancy and live birth

Key consistent benefits of PGT-A have been a reduction in the number of miscarriages, and a decrease in the number of transfers required to achieve a healthy live birth.

Numerous studies (e.g., SART, ESTEEM) have repeatedly demonstrated the benefit of PGT-A, with reductions of miscarriage rates identified across all age groups.

PGT-A reduces miscarriage rates¹



References:


1. Final unpublished SART data from 2014–2016 and preliminary SART data for 2017. Data provided by, and published with permission from, Dr David McCulloh
2. CoGEN (Controversies in Preconception, Preimplantation and Prenatal Genetic Diagnosis) Position Statement: <https://ivf-worldwide.com/cogen/general/cogen-statement.html>
3. PGDIS (Preimplantation Genetic Diagnosis International Society) Position Statement: https://www.pgdis.org/docs/newsletter_071816.html
4. Buldo-Licciardi et al. 2020. Second generation artificial intelligence technology for preimplantation genetic testing (PGT) improves pregnancy outcomes in single thawed

Increase confidence in embryo selection and further reduce miscarriage risk using the PGTai 2.0 platform

Our most accurate technology for identifying euploid embryos as euploid

The PGTai 2.0 platform allows you to be more confident that an embryo identified as euploid is *euploid*:


1. Embryos are reported as euploid when <20% mosaic (see figure below, following society guidelines), meaning we report fewer low-level mosaics as euploid than other PGT-A providers
2. Utilizing an additional methodology (SNPs) alongside NGS/CNV, more reliably identifies and verifies an embryo as euploid
3. It is the only analysis in the IVF field developed using live birth outcomes rather than cell line samples. This establishes a true baseline to ensure that an embryo classified as euploid is unequivocally euploid



NYU Study shows patients' chances of having a baby improved with the PGTai 2.0 platform!⁴

- This single-centre study shows the innovative PGTai 2.0 platform helped patients fulfill their ultimate dream of having a baby; ongoing pregnancy and live birth rates were increased from **61.65%** to **70.32%**
- Study results also showed the devastating outcome of early pregnancy loss rates were almost halved; a reduction from **11.8%** to **4.64%** was shown with the innovative platform.






At CARE Fertility, we have been impressed with the transition from standard to PGTAi; the staff education and clarity of reporting. In addition, we are reassured by the increased precision of this test and believe it brings benefits for our patients.



Alison Campbell

Director of Embryology, CARE Fertility Group, London, UK

With the PGTAi platform we've seen an increase in the number euploid embryos reported as well as an increase in the percentage of patients with at least 1 euploid embryo reported, providing greater transfer opportunities



Relative percentage increase in the number of patients who have at least 1 euploid embryo

Sample sizes are shown alongside the data bars in the format (n=prior [subjective] methodology:PGTAi platform)

CooperGenomics internal data: prior (subjective) methodology, Jan 1, 2018 through Nov 1, 2018 vs PGTAi technology platform, Nov 2, 2018 through May 31, 2019

©2020 CooperSurgical, Inc. All Rights Reserved · Order No. GEN_FLY_016_V3_US · Nov 11, 2020 · All information correct at time of print. Testing is performed by Progenetics, Recombine, Genesis Genetics or other clinical laboratories affiliated with CooperGenomics.